000K utf8 1100 $c2016 1500 eng 2050 urn:nbn:de:gbv:8-publ-24249 2051 10.3389/fnagi.2016.00121 3000 Lerche, Stefanie 3010 Alves, Guido W. 3010 Barone, Paolo 3010 Behnke, Stefanie 3010 Ben-Shlomo, Yoav 3010 Berendse, Henk 3010 Berg, Daniela Dagmar Denise 3010 Bloem, Bastiaan R. 3010 Burn, David 3010 Dodel, Richard 3010 Grosset, Donald G. 3010 Heinzel, Sebastian 3010 Hipp, Geraldine 3010 Hu, Michele T. 3010 Kasten, Meike 3010 Krüger, Rejko 3010 Liepelt-Scarfone, Inga 3010 Mätzler, Walter 3010 Moccia, Marcello 3010 Mollenhauer, Brit 3010 Oertel, Wolfgang 3010 Roeben, Benjamin 3010 Walter, Uwe 3010 Wirdefeldt, Karin 4000 Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies [Lerche, Stefanie] 4209 Parkinson’s disease (PD) is an example for a complex field of research, which is driven by themultifactorial etiology, the heterogeneity in phenotype and the variability in disease progression,as well as the presence of a long pre-diagnostic period, called prodromal PD, lasting up to decades(Postuma et al., 2010). The very slow, so far inevitably progressive, neurodegenerative process andthe multidimensional heterogeneity of symptoms in kind (motor and non-motor), time of onsetand speed of progression call for prediction markers and progression markers to understand theonset of neurodegeneration and its course. These markers would also help to establish endpointsfor neuroprotective treatment strategies aiming to modify disease progression. Because of thecomplexity, heterogeneity, and the progressive nature of PD, such predictive and progressionmarkers can only be identified in large cohorts and in studies with a longitudinal design. 4950 https://doi.org/10.3389/fnagi.2016.00121$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8-publ-24249$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/publ_mods_00002424 5051 610 5550 Biomarker 5550 Longitudinal Studies 5550 Modular Set 5550 Parkinson's Disease